
|Videos|December 23, 2020
ASH 2020 Updates: Improving Outcomes in TIE-NDMM
Author(s)Targeted Oncology
Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5









































